Roberta Di Blasi

4.3k total citations
41 papers, 762 citations indexed

About

Roberta Di Blasi is a scholar working on Oncology, Electrical and Electronic Engineering and Molecular Biology. According to data from OpenAlex, Roberta Di Blasi has authored 41 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 11 papers in Electrical and Electronic Engineering and 6 papers in Molecular Biology. Recurrent topics in Roberta Di Blasi's work include CAR-T cell therapy research (28 papers), Integrated Circuits and Semiconductor Failure Analysis (7 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Roberta Di Blasi is often cited by papers focused on CAR-T cell therapy research (28 papers), Integrated Circuits and Semiconductor Failure Analysis (7 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Roberta Di Blasi collaborates with scholars based in France, Italy and United States. Roberta Di Blasi's co-authors include Simone Cesaro, Catherine Cordonnier, Thomas Lehrnbecher, Hugues de Lavallade, Małgorzata Mikulska, Sigrun Einarsdottir, Per Ljungman, Dan Engelhard, Christina Rieger and Giuseppe Gallo and has published in prestigious journals such as Blood, PLoS ONE and Neurology.

In The Last Decade

Roberta Di Blasi

33 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roberta Di Blasi France 13 459 181 133 128 122 41 762
Noam Benyamini Israel 17 451 1.0× 144 0.8× 289 2.2× 140 1.1× 124 1.0× 53 963
Stanley I. Martin United States 16 228 0.5× 482 2.7× 310 2.3× 82 0.6× 58 0.5× 27 996
Joanna Schaenman United States 17 180 0.4× 305 1.7× 287 2.2× 118 0.9× 41 0.3× 81 897
Isabel Sánchez‐Ortega Spain 17 454 1.0× 404 2.2× 326 2.5× 133 1.0× 108 0.9× 50 1.1k
Fabián Andrés Rosas Romero United States 8 369 0.8× 242 1.3× 114 0.9× 70 0.5× 13 0.1× 13 633
Muhammad Bilal Abid United States 15 294 0.6× 82 0.5× 363 2.7× 78 0.6× 16 0.1× 68 762
Yuki Asano‐Mori Japan 18 251 0.5× 433 2.4× 158 1.2× 171 1.3× 21 0.2× 74 888
Aspasia Georgala Belgium 16 573 1.2× 341 1.9× 169 1.3× 42 0.3× 59 0.5× 35 956
Montserrat Arnán Spain 19 469 1.0× 537 3.0× 418 3.1× 69 0.5× 216 1.8× 53 1.3k
Ioannis G. Baraboutis Greece 15 153 0.3× 188 1.0× 206 1.5× 30 0.2× 34 0.3× 31 549

Countries citing papers authored by Roberta Di Blasi

Since Specialization
Citations

This map shows the geographic impact of Roberta Di Blasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberta Di Blasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberta Di Blasi more than expected).

Fields of papers citing papers by Roberta Di Blasi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberta Di Blasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberta Di Blasi. The network helps show where Roberta Di Blasi may publish in the future.

Co-authorship network of co-authors of Roberta Di Blasi

This figure shows the co-authorship network connecting the top 25 collaborators of Roberta Di Blasi. A scholar is included among the top collaborators of Roberta Di Blasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberta Di Blasi. Roberta Di Blasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bachy, Emmanuel, François‐Xavier Gros, Roberta Di Blasi, et al.. (2025). Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study. Blood Advances. 9(10). 2500–2510.
2.
Galli, Eugenio, Roberta Di Blasi, Alice Di Rocco, et al.. (2025). Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study. Blood Advances. 9(21). 5501–5509.
3.
Blasi, Roberta Di, Louise Roulin, Véronique Meignin, et al.. (2025). TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas. Blood Advances. 9(18). 4693–4704.
4.
Vercellino, Laëtitia, Estelle Blanc, É. de Kerviler, et al.. (2024). Patterns of metabolic response in patients receiving commercial CAR T-cells for relapsing/refractory aggressive B cells lymphoma. British Journal of Radiology. 97(1163). 1755–1764.
5.
Durot, Éric, Damien Roos‐Weil, Adrien Chauchet, et al.. (2024). High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia. Blood. 143(26). 2804–2807. 3 indexed citations
6.
Maillard, Alexis, Alexis Cuffel, Vincent Allain, et al.. (2024). Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy. Journal for ImmunoTherapy of Cancer. 12(9). e009525–e009525. 8 indexed citations
7.
8.
Tabaa, Yassine Al, Clément Bailly, Anne‐Ségolène Cottereau, et al.. (2023). Low Tmtv Influences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry. Blood. 142(Supplement 1). 3019–3019. 1 indexed citations
9.
Ursu, Rénata, Didier Maillet, Cathérine Belin, et al.. (2022). Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Neurology. 99(12). 511–515. 20 indexed citations
10.
Cuffel, Alexis, Vincent Allain, Lionel Faivre, et al.. (2022). Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Advances. 6(15). 4657–4660. 20 indexed citations
11.
12.
Valade, Sandrine, Michaël Darmon, Lara Zafrani, et al.. (2022). The use of ICU resources in CAR-T cell recipients: a hospital-wide study. Annals of Intensive Care. 12(1). 75–75. 10 indexed citations
13.
Galtier, Jean, Laëtitia Vercellino, Loïc Chartier, et al.. (2022). Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells. Haematologica. 108(1). 171–180. 19 indexed citations
14.
Lemoine, Jean, Florence Morin, Roberta Di Blasi, et al.. (2021). Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas. Blood. 138(Supplement 1). 1433–1433. 8 indexed citations
15.
Thiéblemont, Catherine, Sylvie Chevret, Vincent Allain, et al.. (2020). Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion. Blood. 136(Supplement 1). 16–17. 16 indexed citations
16.
Galli, Eugenio, Vincent Allain, Roberta Di Blasi, et al.. (2020). G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplantation. 55(12). 2347–2349. 42 indexed citations
17.
Mikulska, Małgorzata, Simone Cesaro, Hugues de Lavallade, et al.. (2019). Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases. 19(6). e188–e199. 98 indexed citations
18.
Thiéblemont, Catherine, Steven Le Gouill, Roberta Di Blasi, et al.. (2019). S1600 REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM. HemaSphere. 3(S1). 736–737. 2 indexed citations
19.
20.
Blasi, Roberta Di, et al.. (1957). [Accidental vaccinia with nasal localization].. PubMed. 28(1). 85–8.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noam Benyamini Breakdown of academic impact, for papers by Stanley I. Martin Breakdown of academic impact, for papers by Joanna Schaenman Breakdown of academic impact, for papers by Isabel Sánchez‐Ortega Breakdown of academic impact, for papers by Fabián Andrés Rosas Romero Breakdown of academic impact, for papers by Muhammad Bilal Abid Breakdown of academic impact, for papers by Yuki Asano‐Mori Breakdown of academic impact, for papers by Aspasia Georgala Breakdown of academic impact, for papers by Montserrat Arnán Breakdown of academic impact, for papers by Ioannis G. Baraboutis
Rankless by CCL
2026